Status:
WITHDRAWN
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
Lead Sponsor:
Kresge Eye Institute
Collaborating Sponsors:
Wayne State University
Genentech, Inc.
Conditions:
Sickle Cell Anemia
Retinopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.
Detailed Description
In the U.S., about 10% of African Americans have an abnormal hemoglobin gene. About 8% of African Americans are heterozygous for Hemoglobin S. In the United States, sickle cell anemia primarily occurs...
Eligibility Criteria
Inclusion
- Patients with sickle cell anemia and retinopathy
- Over age 18 years
- Non-pregnant
Exclusion
- Pregnant
- Glaucoma
- Patients using anticoagulants (e.g., warfarin)
- Retinal detachment
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00618644
Start Date
January 1 2010
End Date
June 1 2011
Last Update
September 27 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kresge Eye Institute
Detroit, Michigan, United States, 48201